DK3377484T3 - Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet - Google Patents

Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet Download PDF

Info

Publication number: DK3377484T3
Authority: DK; Denmark
Prior art keywords: btk; pyrimidine; treatment; methods; multiple sclerosis
Prior art date: 2015-11-17

Application number

DK16805251.2T

Other languages

English (en)

Inventor

Tammy Dellovade

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-17

Filing date

2016-11-16

Publication date

2023-11-27

2016-11-16 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2023-11-27 Application granted granted Critical

2023-11-27 Publication of DK3377484T3 publication Critical patent/DK3377484T3/da

Links

JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
201000006417 multiple sclerosis Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

DK16805251.2T 2015-11-17 2016-11-16 Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet DK3377484T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562256199P	2015-11-17	2015-11-17
PCT/US2016/062154 WO2017087445A1 (en)	2015-11-17	2016-11-16	Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity

Publications (1)

Publication Number	Publication Date
DK3377484T3 true DK3377484T3 (da)	2023-11-27

Family

ID=57460611

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16805251.2T DK3377484T3 (da)	2015-11-17	2016-11-16	Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet

Country Status (26)

Country	Link
US (2)	US10716788B2 (da)
EP (2)	EP4295910A3 (da)
JP (1)	JP6891173B2 (da)
KR (1)	KR20180080243A (da)
CN (1)	CN108884076B (da)
AU (1)	AU2016357735B2 (da)
BR (1)	BR112018007517B1 (da)
CA (1)	CA3002224A1 (da)
CL (1)	CL2018001252A1 (da)
DK (1)	DK3377484T3 (da)
ES (1)	ES2964946T3 (da)
FI (1)	FI3377484T3 (da)
HR (1)	HRP20231547T1 (da)
HU (1)	HUE064244T2 (da)
IL (1)	IL258978B (da)
LT (1)	LT3377484T (da)
MX (1)	MX2018005463A (da)
NZ (1)	NZ741294A (da)
PH (1)	PH12018500736A1 (da)
PL (1)	PL3377484T3 (da)
PT (1)	PT3377484T (da)
RS (1)	RS64908B1 (da)
SI (1)	SI3377484T1 (da)
UA (1)	UA123159C2 (da)
WO (1)	WO2017087445A1 (da)
ZA (1)	ZA201802348B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2022100782A (ru) *	2015-11-04	2022-02-03	Мерк Патент Гмбх	Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
UA123159C2 (uk) *	2015-11-17	2021-02-24	Мерк Патент Гмбх	Способи лікування розсіяного склерозу з використанням сполук піримідину і піридину з btk-інгібувальною активністю
EP3810590A1 (en) *	2018-06-19	2021-04-28	Merck Patent GmbH	Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
TW202019425A (zh) *	2018-07-20	2020-06-01	德商馬克專利公司	利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法
WO2021150476A1 (en)	2020-01-20	2021-07-29	Genzyme Corporation	Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
CN112250666B (zh) *	2020-10-09	2022-01-14	广东东阳光药业有限公司	取代的嘧啶类化合物及其用途
US11866421B2 (en)	2021-05-31	2024-01-09	Epigen Biosciences, Inc.	Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
WO2023247774A1 (en)	2022-06-24	2023-12-28	Merck Patent Gmbh	Treatment regimen for autoimmune diseases and inflammatory diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR038955A1 (es) *	1996-12-05	2005-02-02	Amgen Inc	Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
CN101676285A (zh) *	2004-03-30	2010-03-24	沃泰克斯药物股份有限公司	用作jak和其它蛋白激酶抑制剂的氮杂吲哚
GB0512844D0 (en) *	2005-06-23	2005-08-03	Novartis Ag	Organic compounds
KR101315610B1 (ko) *	2006-09-22	2013-10-10	파마시클릭스, 인코포레이티드	브루톤 티로신 키나제 억제제
EP2211615A4 (en) *	2007-10-22	2010-10-13	Glaxosmithkline Llc	PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
KR101481872B1 (ko)	2009-09-10	2015-01-12	에프. 호프만-라 로슈 아게	Ｊａｋ의 억제제
KR101301533B1 (ko)	2010-02-09	2013-09-04	한미사이언스 주식회사	암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
CN103814016B (zh) *	2011-06-10	2017-03-08	默克专利有限公司	生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法
UY34893A (es) *	2012-07-10	2014-02-28	Takeda Pharmaceutical	Derivados de azaindol
US20150291554A1 (en) *	2012-11-02	2015-10-15	Pfizer Inc.	Bruton's Tyrosine Kinase Inhibitors
WO2014093230A2 (en) *	2012-12-10	2014-06-19	Merck Patent Gmbh	Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
EP2982666B1 (en) *	2013-04-04	2019-08-07	Takeda Pharmaceutical Company Limited	Heterocyclic compound
MX355943B (es) *	2013-06-26	2018-05-07	Abbvie Inc	Carboxamidas primarias como inhibidores de btk.
CN105814057B (zh) *	2013-07-31	2019-05-03	默克专利有限公司	用作btk抑制剂的嘧啶、吡啶和吡嗪及其用途
JP6494633B2 (ja) *	2013-09-22	2019-04-03	キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒＳｃｉｅｎｃｅｓ，Ｌｌｃ	置換されているアミノピリミジン化合物および使用方法
RU2022100782A (ru) *	2015-11-04	2022-02-03	Мерк Патент Гмбх	Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
UA123159C2 (uk) *	2015-11-17	2021-02-24	Мерк Патент Гмбх	Способи лікування розсіяного склерозу з використанням сполук піримідину і піридину з btk-інгібувальною активністю

2016
- 2016-11-16 UA UAA201806687A patent/UA123159C2/uk unknown
- 2016-11-16 EP EP23195454.6A patent/EP4295910A3/en active Pending
- 2016-11-16 CN CN201680078780.9A patent/CN108884076B/zh active Active
- 2016-11-16 LT LTEPPCT/US2016/062154T patent/LT3377484T/lt unknown
- 2016-11-16 HU HUE16805251A patent/HUE064244T2/hu unknown
- 2016-11-16 BR BR112018007517-5A patent/BR112018007517B1/pt active IP Right Grant
- 2016-11-16 WO PCT/US2016/062154 patent/WO2017087445A1/en active Application Filing
- 2016-11-16 SI SI201631768T patent/SI3377484T1/sl unknown
- 2016-11-16 ES ES16805251T patent/ES2964946T3/es active Active
- 2016-11-16 HR HRP20231547TT patent/HRP20231547T1/hr unknown
- 2016-11-16 PT PT168052512T patent/PT3377484T/pt unknown
- 2016-11-16 AU AU2016357735A patent/AU2016357735B2/en active Active
- 2016-11-16 PL PL16805251.2T patent/PL3377484T3/pl unknown
- 2016-11-16 CA CA3002224A patent/CA3002224A1/en active Pending
- 2016-11-16 KR KR1020187014258A patent/KR20180080243A/ko not_active Application Discontinuation
- 2016-11-16 US US15/352,657 patent/US10716788B2/en active Active
- 2016-11-16 MX MX2018005463A patent/MX2018005463A/es unknown
- 2016-11-16 FI FIEP16805251.2T patent/FI3377484T3/fi active
- 2016-11-16 NZ NZ741294A patent/NZ741294A/en unknown
- 2016-11-16 DK DK16805251.2T patent/DK3377484T3/da active
- 2016-11-16 EP EP16805251.2A patent/EP3377484B1/en active Active
- 2016-11-16 RS RS20231155A patent/RS64908B1/sr unknown
- 2016-11-16 JP JP2018525702A patent/JP6891173B2/ja active Active
2018
- 2018-04-03 PH PH12018500736A patent/PH12018500736A1/en unknown
- 2018-04-10 ZA ZA2018/02348A patent/ZA201802348B/en unknown
- 2018-04-26 IL IL258978A patent/IL258978B/en active IP Right Grant
- 2018-05-09 CL CL2018001252A patent/CL2018001252A1/es unknown
2020
- 2020-06-08 US US16/946,145 patent/US20200316068A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HRP20231547T1 (hr)	2024-03-15
EP4295910A2 (en)	2023-12-27
US10716788B2 (en)	2020-07-21
ZA201802348B (en)	2020-08-26
JP2018538264A (ja)	2018-12-27
AU2016357735A1 (en)	2018-04-26
EP3377484A1 (en)	2018-09-26
RU2018120151A (ru)	2019-12-18
BR112018007517B1 (pt)	2023-09-26
RS64908B1 (sr)	2023-12-29
NZ741294A (en)	2023-07-28
WO2017087445A1 (en)	2017-05-26
CN108884076B (zh)	2021-07-30
IL258978A (en)	2018-07-31
US20170136018A1 (en)	2017-05-18
LT3377484T (lt)	2023-12-27
US20200316068A1 (en)	2020-10-08
UA123159C2 (uk)	2021-02-24
KR20180080243A (ko)	2018-07-11
CL2018001252A1 (es)	2018-08-17
PT3377484T (pt)	2023-12-14
EP4295910A3 (en)	2024-03-20
ES2964946T3 (es)	2024-04-10
CN108884076A (zh)	2018-11-23
FI3377484T3 (fi)	2023-11-30
AU2016357735B2 (en)	2021-01-14
HUE064244T2 (hu)	2024-02-28
CA3002224A1 (en)	2017-05-26
IL258978B (en)	2021-04-29
BR112018007517A2 (pt)	2018-10-23
RU2018120151A3 (da)	2020-03-24
PL3377484T3 (pl)	2024-04-08
PH12018500736A1 (en)	2018-10-01
SI3377484T1 (sl)	2024-02-29
MX2018005463A (es)	2018-08-01
JP6891173B2 (ja)	2021-06-18
EP3377484B1 (en)	2023-09-06

Publication	Publication Date	Title
DK3377484T3 (da)	2023-11-27	Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet
DK3331915T3 (da)	2021-05-03	Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3253865T3 (da)	2022-08-15	Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller
KR20180084817A (ko)	2018-07-25	항-siglec-9 항체 및 이의 이용 방법
DK3356350T3 (da)	2022-12-19	Isoindolinonhæmmere af mdm2-p53-interaktionen med anticanceraktivitet
DK3119397T3 (da)	2022-03-28	Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3240773T3 (da)	2020-09-07	Picolinamidforbindelser med fungicid aktivitet
DK3521282T3 (da)	2021-09-27	Quinazolinderivater anvendt til behandling af hiv
DK3139925T3 (da)	2021-12-20	Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser
DK3307262T3 (da)	2021-08-09	Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3481846T3 (da)	2021-08-16	11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3285803T3 (da)	2020-02-17	Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine
DK3303339T3 (da)	2021-04-12	Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3350201T3 (da)	2022-03-07	Manipulerede fytaser og fremgangsmåder til anvendelse af samme
DK3362066T3 (da)	2021-11-22	Kombinationsterapi til behandling af maligniteter
DK3882250T3 (da)	2023-05-22	Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3099298T3 (da)	2019-05-27	Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3157534T3 (da)	2022-08-22	Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
SG10202005292UA (en)	2020-07-29	Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
DK3331879T3 (da)	2020-08-10	Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3307296T3 (da)	2021-12-13	Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3253412T3 (da)	2022-05-23	Anti-cd40l-antistoffer og fremgangsmåder til behandling af cd40l-forbundne sygdomme eller forstyrrelser
DK3606929T3 (da)	2021-08-23	Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme
DK3391902T3 (da)	2023-11-20	Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati